A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring

Frontiers in Medicine

Volumn 2, Issue MAR, 2015, Pages 13-

  Anwar, Siddiq ^a   Larson, Derek S ^a   Naimi, Nima ^a   Ashraf, Muhammad ^a   Culiberk, Nancy ^a   Liapis, Helen ^a   Wei, Changli ^b   Reiser, Jochen ^b   Brennan, Daniel C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Albumin permeability factor; Angiotensin 1 receptor antibody; Podocyte; Recurrent focal segmental glomerular sclerosis; Soluble urokinase plasminogen activator receptor

Indexed keywords

EID: 84974592821     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00013     Document Type: Article

References (34)

1. Pinto J, Lacerda G, Cameron JS, Turner DR, Bewick M, Ogg CS. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation (1981) 32:83-9. doi:10.1097/00007890-198108000-00001
2. Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol (2001) 12:394-402.
3. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant (2006) 6:2535-42. doi:10.1111/j.1600-6143.2006.01502.x
4. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American pediatric renal transplant cooperative study. J Am Soc Nephrol (1992) 2:S258-63.
5. Savin VJ, Sharma R, Sharma M, Mccarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med (1996) 334:878-83. doi:10.1056/NEJM199604043341402
6. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2010) 5:2115-21. doi:10.2215/CJN.03800609
7. Avila-Casado Mdel C, Perez-Torres I, Auron A, Soto V, Fortoul TI, Herrera-Acosta J. Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. Kidney Int (2004) 66:133-43. doi:10.1111/j.1523-1755.2004.00715.x
8. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 23:2051-9. doi:10.1681/ASN.2012030302
9. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med (2013) 368:971-3. doi:10.1056/NEJMc1207233
10. Bomback AS, Canetta PA, Beck LHJ, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol (2012) 36:56-8. doi:10.1159/000339287
11. Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol (2013) 8:2072-8. doi:10.2215/CJN.02840313
12. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 17:952-60. doi:10.1038/nm.2411
13. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol (2010) 5(12):2363-72. doi:10.2215/CJN.06720810
14. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3:85ra46. doi:10.1126/scitranslmed.3002231
15. Cho JH, Lee JH, Park GY, Lim JH, Kim JS, Kang YJ, et al. Successful treatment of recurrent focal segmental glomerulosclerosis with a low dose rituximab in a kidney transplant recipient. Ren Fail (2014) 36:623-6. doi:10.3109/0886022X.2014.882238
16. Spinner ML, Bowman LJ, Horwedel TA, Delos Santos RB, Klein CL, Brennan DC. Single-dose rituximab for recurrent glomerulonephritis post-renal transplant. Am J Nephrol (2015) 41:37-47. doi:10.1159/000371587
17. Savin VJ, Mccarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res (2008) 151:288-92. doi:10.1016/j.trsl.2008.04.001
18. De Smet E, Rioux JP, Ammann H, Deziel C, Querin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant (2009) 24:2938-40. doi:10.1093/ndt/gfp278
19. Pascual J, Mezrich JD, Djamali A, Leverson G, Chin LT, Torrealba J, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation (2007) 83:1429-34. doi:10.1097/01.tp.0000264554.39645.74
20. Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R, US Thymoglobulin Multi-Center Study Group. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol (2001) 9:29-36. doi:10.1016/S0966-3274(01)00048-X
21. Trachtman H. suPAR and team nephrology. BMC Med (2014) 12:82. doi:10.1186/1741-7015-12-82
22. Bock ME, Price HE, Gallon L, Langman CB. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol (2013) 8:1304-11. doi:10.2215/CJN.07680712
23. Peng Z, Mao J, Chen X, Cai F, Gu W, Fu H, et al. Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol (2014) 30(2):301-7. doi:10.1007/s00467-014-2892-6
24. Schlondorff D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int (2014) 85:499-501. doi:10.1038/ki.2013.549
25. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 96:394-9. doi:10.1097/TP.0b013e3182977ab1
26. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med (2014) 12:81. doi:10.1186/1741-7015-12-81
27. Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol (2006) 290:F710-9. doi:10.1152/ajprenal.00475.2004
28. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, Van Goor H, Kistler AD, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol (2011) 179:1719-32. doi:10.1016/j.ajpath.2011.06.033
29. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 352:558-69. doi:10.1056/NEJMoa035717
30. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med (2008) 14:855-62. doi:10.1038/nm.1856
31. Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis (2011) 70:530-6. doi:10.1136/ard.2010.135772
32. H.P. Acthar Gel Prescribing Information. Hayward, C.Q.P.I. (0000). Available from: http://www.actharhcp.com/proteinuria-in-nephrotic-syndrome/acthar-and-proteinuria-in-nephrotic-syndrome.html
33. Bomback AS, Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med (2011) 12:91-6.
34. Akkina S. Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients. (2014). ClinicalTrials.gov Identifier: NCT02057523.